Abstract:Wen Ting Zhu, 1, &ast Xiang Feng Zeng, 2, &ast Hua Yang, 2 Meng Lei Jia, 1 Wei Zhang, 2 Wei Liu, 2 Sheng Yao Liu 3 1 Department of Pharmacy, Biomedicine Research Center, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, People's Republic of China; 2 Department of Orthopedics, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, People's Republic of China; 3 Department of Orthopedics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Liu, Department of Orthopedics, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, People's Republic of China, Email Sheng Yao Liu, Department of Orthopedics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, People's Republic of China, Email Background: Osteosarcoma is a malignant bone tumor with a high rate of lung metastasis and mortality. It has been demonstrated that resveratrol can inhibit tumor proliferation and metastasis, but its application is limited due to poor water solubility and low bioavailability. In this study, we proposed to prepare folate-modified liposomes loaded with resveratrol to investigate its anti-osteosarcoma effect in vitro and in vivo. Methods: We prepared and characterized resveratrol liposomes modified with folate (denoted as, FA-Res/Lps). The effects of FA-Res/Lps on human osteosarcoma cell 143B proliferation, apoptosis, and migration were investigated by MTT, cell cloning, wound-healing assay, transwell, and flow cytometry. A xenograft tumor and lung metastasis model of osteosarcoma was constructed to study the therapeutic effects of FA-Res/Lps on the growth and metastasis of osteosarcoma in vivo. Results: The FA-Res/Lps were prepared with a particle size of 118.5 ± 0.71 and a small dispersion coefficient of 0.154 ± 0.005. We found that FA-modified liposomes significantly increased resveratrol uptake by osteosarcoma cells 143B in flow cytometric assay, resulting in FA-Res/Lps, which inhibit tumor proliferation, migration and induce apoptosis more effectively than free Res and Res/Lps. The mechanism of action may be associated with the inhibition of JAK2/STAT3 signaling. In vivo imaging demonstrated that FA-modified DiR-modified liposomes significantly increased the distribution of drugs at the tumor site, leading to significant inhibition of osteosarcoma growth and metastasis by FA-Res/Lps. Furthermore, we found that FA-Res/Lps did not cause any adverse effects on mice body weight, liver, or kidney tissues. Conclusion: Taken together, the anti-osteosarcoma effect of resveratrol is significantly enhanced when it is loaded into FA-modified liposomes. FA-Res/Lps is a promising strategy for the treatment of osteosarcoma. Keywords: resveratrol, liposomes, osteosarcoma, lung metastasis, JAK2/STAT3 pathway Osteosarcoma (OS) is the most common malignant bone tumor. Most cases occur in children and young adults 10 to 30 years of age. Approximately 10 to 15% of patients with newly diagnosed osteosarcoma present with metastatic disease, primarily in the lung. The 5-year survival rate is approximately 60% among patients with localized osteosarcoma but is only 20% among patients presenting with metastases or recurrent disease. 1,2 The mainstay of treatment for OS is surgical resection of the primary tumor, pre-and post-operative chemotherapy has been effective in improving patient survival. Unfortunately, chemotherapeutic drugs are not good for treating OS lung metastases and are susceptible to toxic side effects, such as adriamycin, which has significant cardiac effects, so it is urgent to find a highly effective and less toxic drug for treating OS. 3,4 Nowadays, scientists are investigating the use of various naturally-occurring bioactive compounds against OS. 5,6 Resveratrol (Res), a non-flavonoid polyphenolic organic compound, has antioxidant, anti-inflammatory, 7 anti-cancer, 8 and cardiovascular protection. 9 Furthermore, Res has a significant inhibitory effect on a wide range of tumor cells, including hepatocellular carcinoma, 10 breast cancer, 11 colon cancer, 12 gastric cancer 13 , and leukemia. 14 Res has been demonstrated that it can inhibit the growth and metastasis of OS in vitro through NF-κB inhibition 15 and STAT3 pathway inhibition, 16 -Abstract Truncated-

In silico studies reveal the anti-osteosarcoma targets and action mechanisms of resveratrol

The Role of CTLA-4 and PD-1 in Anti-Tumor Immune Response and Their Potential Efficacy Against Osteosarcoma

Identification of therapeutic targets for osteosarcoma by integrating single-cell RNA sequencing and network pharmacology

Identification of anti-gastric cancer effects and molecular mechanisms of resveratrol: From network pharmacology and bioinformatics to experimental validation

Dual Mechanism of Action of Resveratrol in Notch Signaling Pathway Activation in Osteosarcoma

T52 Attenuates Oncogenic STAT3 Signaling and Suppresses Osteosarcoma.

Resveratrol promotes osteogenesis and alleviates osteoporosis by inhibiting p53

Pharmacological Biotargets and the Molecular Mechanisms of Oxyresveratrol Treating Colorectal Cancer: Network and Experimental Analyses.

Resveratrol is Cytotoxic and Acts Synergistically with NF-κB Inhibition in Osteosarcoma MG-63 Cells.

Research Progress in Elucidating the Mechanisms Underlying Resveratrol Action on Lung Cancer

Network pharmacology and experimental verification-based strategy for exploring the mechanisms of luteolin in the treatment of osteosarcoma

Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis

Integrated Multiomic Analysis and High-Throughput Screening Reveal Potential Gene Targets and Synergetic Drug Combinations for Osteosarcoma Therapy

Anti‐colorectal cancer targets of resveratrol and biological molecular mechanism: Analyses of network pharmacology, human and experimental data

Resveratrol Loaded by Folate-Modified Liposomes Inhibits Osteosarcoma Growth and Lung Metastasis via Regulating JAK2/STAT3 Pathway

Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor Inflammation Based on Transcriptional Spectrum Analysis and Drug Library Screening

A Network Pharmacology Guided Mechanism of Action Study on <i>Oldenlandia diffusa</i> Against Osteosarcoma

Predictive Study of the Active Ingredients and Potential Targets of Codonopsis pilosula for the Treatment of Osteosarcoma via Network Pharmacology

Abstract number:11171 The anti-tumor potential of some naturally active substances isolated from Chinese medicinal herbs in Osteosarcoma

Inhibition of STAT3 Signaling As Critical Molecular Event in Resveratrol-Suppressed Ovarian Cancer Cells.

Ten-gene signature reveals the significance of clinical prognosis and immuno-correlation of osteosarcoma and study on novel skeleton inhibitors regarding MMP9